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Abstract
Objectives: Fatigue is a major cause of disability in primary Sjo ¨gren’s syndrome (pSS). Fatigue has similarities with sickness
behaviour in animals; the latter mediated by pro-inflammatory cytokines, in particular interleukin (IL)-1, acting on neuronal
brain cells. We hypothesised that IL-1 inhibition might improve fatigue in pSS patients; thus, we examined the effects and
safety of an IL-1 receptor antagonist (anakinra) on fatigue.
Methods: Twenty-six pSS patients participated in a double-blind, placebo-controlled parallel group study. Patients were
randomised to receive either anakinra or a placebo for four weeks. Fatigue was evaluated by a fatigue visual analogue scale
and the Fatigue Severity Scale. The primary outcome measure was a group-wise comparison of the fatigue scores at week 4,
adjusted for baseline values. Secondary outcome measures included evaluation of laboratory results and safety. The
proportion of patients in each group who experienced a 50% reduction in fatigue was regarded as a post-hoc outcome. All
outcomes were measured at week 4.
Results: There was no significant difference between the groups in fatigue scores at week 4 compared to baseline after
treatment with anakinra. However, six out of 12 patients on anakinra versus one out of 13 patients on the placebo reported
a 50% reduction in fatigue VAS (p=0.03). There were two serious adverse events in each group.
Conclusions: This randomised, double-blind, placebo-controlled trial of IL-1 blockade did not find a significant reduction in
fatigue in pSS in its primary endpoint. A 50% reduction in fatigue was analysed post-hoc, and significantly more patients on
the active drug than on placebo reached this endpoint. Although not supported by the primary endpoint, this may indicate
that IL-1 inhibition influences fatigue in patients with pSS.
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Introduction
Primary Sjo ¨gren’s syndrome (pSS) is a chronic autoimmune
disease with an estimated prevalence of 0.05%–0.5% [1,2].
Clinical characteristics are dryness of the mouth and eyes –
xerostomia and keratoconjunctivitis sicca. Histopathological
examination reveals lymphocytic infiltration in exocrine glands,
sometimes with ectopic germinal centre formation [3]. The
majority of patients have autoantibodies against the ribonuclein
particles SSA/Ro and/or SSB/La. Patients frequently have
extraglandular manifestations such as muscle and joint pain,
neuropathy, and fatigue [4]. Fatigue is a major cause of disability
[5]. Recently it was reported that 85% of pSS patients experience
fatigue, and 40% of the patients report fatigue as their most
severe symptom [6]. It is well known that mood disorders
influence fatigue, but in pSS fatigue occurs in non-depressed as
well as depressed individuals [7,8]. Other factors influencing
fatigue in pSS are pain, sleep disorders, learned helplessness, and
possibly neuroendocrine disturbances and autonomic dysfunction
[9].
In search of biological mechanisms for fatigue we and others
have found sickness behaviour in animals to be a relevant model [10].
In animals, this behaviour is an adaptive and appropriate response
to infection and inflammation, and is characterised by increased
sleep, decreased activity, social withdrawal, and loss of appetite
[10]. A number of animal studies have demonstrated that sickness
behaviour is signalled through interleukin (IL)-1 receptors on
neurons in the brain [11]. This is exemplified by intraperitoneal
(IP) or intracerebroventricular (ICV) injections of IL-1b or
lipopolysaccharide (LPS), which leads to sickness behaviour within
a few hours [12]. There is no such effect following LPS-injections
in IL-1 knockout mice [13]. IL-1 exists in a membrane bound
form (IL-1a) and a circulating form (IL-1b) and has two receptors:
IL-1RI induces signal transduction, while IL-1RII functions as a
decoy receptor [14]. A naturally occurring IL-1 receptor
antagonist (IL-1Ra) inhibits IL-1 signalling by competitive binding
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recombinant IL-1Ra administered systemically may inhibit the
effect of IL-1 in the brain [16]. Injection of recombinant IL-1Ra in
animals before injection of LPS diminishes sickness behaviour
[17].
Injection of IL-1 in humans leads to fever, fatigue, and nausea
[18,19]. We recently demonstrated that increased activation in the
IL-1 system, as detected by raised levels of IL-1Ra in cerebrospinal
fluid (CSF), is associated with more fatigue in pSS [7].
The mapping of biological pathways associated with fatigue is
important in order to understand the phenomenon and to point
out possible new treatment targets. Anakinra is a recombinant IL-
1Ra used in the treatment of rheumatoid arthritis (RA), adult
Still’s disease, and autoinflammatory diseases. It is administered
daily by a subcutaneous injection. Administration of anakinra
reduced fatigue in a non-blinded pilot trial in RA patients [20].
We hypothesised that fatigue in pSS is mediated through
activation of IL-1 receptors in the brain analogue to sickness
behaviour in animals. Inhibition of these receptors may lead to a
reduction in fatigue; thus, the objective of the current study was to
investigate the effect of IL-1 inhibition on fatigue in pSS.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
All patients gave written informed consent to participate, and
the study (ClinicalTrials.gov number NCT00683345) was ap-
proved by the regional ethics committee, REK-Nord, Norway,
and carried out in compliance with the principles expressed in the
Declaration of Helsinki.
Patients
We reviewed the medical records of all pSS patients between
the ages of 18–80 years who lived in Rogaland County, Norway in
2008. Eligible participants were of Western European descent, met
the 2002 American-European Consensus Group criteria for pSS
[21], and spoke Norwegian. Exclusion criteria were: untreated
comorbid conditions influencing fatigue (i.e. untreated hypothy-
roidism, heart failure), significant depression (score $20 on the
Beck Depression Inventory (BDI) [22]), no fatigue measured by
the Fatigue Severity Scale (FSS) [23] (score #3), anaemia
(haemoglobin ,100 g/L), neutropenia (neutrophil count
,1.5610
9/L), actual or recurrent infections, pregnancy or
lactation, or concurrent treatment with biological drugs.
One hundred and twenty-five pSS patients were registered in
Rogaland County in 2008, of which 26 were deemed to be
ineligible. Thus, 99 patients were invited by letter to participate in
the study. For logistic reasons, the study was conducted in two
phases, a pilot study in 2008 and the main study in 2010. Of the 15
patients who agreed to participate in 2008, eight were included.
The remaining 84 patients were invited to participate in the 2010
study and 18 were included. A flow chart visualizing the inclusion
and reasons for non-inclusion is provided in Figure 1. In total, 26
of 125 (21%) pSS patients, 19 women (73%) and seven men (27%),
were randomised to receive treatment.
Study design and visits
The study was designed as a single centre, prospective,
randomised, double-blind, placebo-controlled parallel group trial.
Patients had a total of five study visits; baseline (inclusion), week 0,
week 2, week 4, and week 5. Baseline evaluation included medical
history and physical examination. Venous blood samples were
drawn at each study visit for routine haematological and
biochemical tests and assessment of autoantibodies and comple-
ment. Fatigue was assessed at all study visits, and depression was
assessed at baseline and week 5. All study visits took place at
Stavanger University Hospital.
Measures
The FSS and a fatigue visual analogue scale (VAS) were used to
assess fatigue. The FSS is a generic, unidimensional fatigue
instrument [23], which has been validated and is used in a number
of diseases including pSS [24]. The patient evaluates 9 items,
giving each item a score of 1 to 7. The FSS score is the mean score
and a higher FSS score indicates more fatigue. A FSS score of 3 is
commonly used as a cut-off value for fatigue in systemic lupus
erythematosus (SLE) and was applied in this study. The fatigue
VAS used was a horizontal 100 mm line with vertical anchoring
lines. The description used at the left end (0 mm) was ‘‘No fatigue’’
and at the right end (100 mm) was ‘‘Fatigue as bad as it can be’’.
Mood was assessed with the BDI, which is a widely used
instrument to evaluate the current level of depression. A BDI score
below 13 represent no depression, while a score of 14–19 reflects
mild depression. A cut-off score of $20 was used to exclude
moderately to severely depressed individuals. Mood was only
assessed at inclusion and at week 5.
Study drug and randomisation
Patients were randomly assigned to receive double-blinded
therapy with anakinra (Kineret
TM, BioVitrum AB, SE-112 76
Stockholm, Sweden) 100 mg/day or a placebo (0.9% NaCl in
identical syringes) for four weeks. Anakinra or the placebo was
injected subcutaneously over 30 seconds in the abdominal or thigh
region. The assigned treatment was withheld when infection or
fever was present. The first injection was given at week 0 and the
last at week 4. Endpoints were predetermined to be measured at
week 4, as we expected fatigue to return to baseline at week 5, due
to the short half-life of anakinra. Allocation of the participants was
performed after complete inclusion using a computer generated
randomisation list administered by the hospital pharmacy. Simple
randomisation was used, with a 1:1 allocation to either active drug
or placebo. Neither the patients, investigators, nor the study nurses
were aware of the assigned treatment.
The study had to be conducted in two phases due to initial
problems with placebo-production; a pilot study in 2008 and the
main study in 2010. It was not possible to produce the placebo in
syringes identical to the active drug in 2008; therefore, all patients
received their daily injections at the hospital. One of the
investigators was present at every study visit during the four
weeks of the study and supervised the drug injections made by one
of two study nurses. The participants, nurses, and investigators
were blinded to the randomisation. A research nurse, who was
unblinded and not involved in patient handling, prepared the
active drug and placebo in identical syringes for injection. Safety
assessments were completed at every visit, and there were no
missing cases. The results of the 2008 pilot study were blinded
until interim analysis in 2009, revealing a non-significant trend
towards a reduction in fatigue in the patients on the active drug.
The hospital pharmacy could produce placebo in syringes
identical to the active drug in 2010, with a durability that allowed
the patients to receive a 14 days supply of the assigned treatment
at week 0 and week 2. The patients were trained to self administer
the injection of either active drug or placebo, and administered the
first injection under supervision at week 0. The patients registered
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syringes were collected at the study visit at week 2 and week 4.
Safety assessments were completed at every visit. Due to infections,
two patients failed to attend, one at week 4 and one at week 5.
Outcome measures
The primary outcome measure was a group-wise comparison of
fatigue scores at week 4, adjusted for baseline values. Secondary
outcome measures were change in fatigue scores within each
treatment group during the study, and safety and tolerability of
anakinra in pSS. The proportion of patients achieving a 50%
reduction in fatigue from baseline to week 4 in the active treatment
group, as compared to the placebo group, was analysed as a post-
hoc outcome. We regarded this as a robust measure as a 20%
reduction in fatigue VAS score had been used in another recent
study on rituximab-treated pSS patients [25].
Blood analysis
Blood samples were collected at baseline, week 0, week 2, week
4, and week 5. Routine haematological tests and biochemical tests,
including differential blood cell count, haemoglobin, CRP, ESR,
creatinine, glomerular filtration rate (GFR), ASAT, and ALAT
were performed at the hospital’s analytical laboratory. Antinuclear
antibodies (ANA) and antibodies to SSA/Ro and SSB/La were
analysed as previously described [26].
Sample size calculation
Based on a prior study of anakinra treatment for fatigue in RA
[20], we estimated that 30 patients were needed to detect a
difference in 25 points on the fatigue VAS with a power of 80%
and a two-sided a of 0.05.
Statistics
The results from the 26 patients were analysed as one cohort.
Results are reported as mean 6 standard deviation (SD) when
normally distributed, otherwise as median and range. The t-test
and Fisher’s exact test were used for the comparison of continuous
and categorical data, respectively. ANCOVA was used to compare
fatigue scores at week 4 between groups. Due to the small sample
size and the distribution of data, the non-parametric Friedman
Test for repeated measures was used to analyse changes over time
within groups. A p-value of ,0.05 was defined as statistical
significant. All analyses were carried out using SPSS for Windows
version 16.0.
Results
Thirteen of the 26 patients included were randomised to receive
the active drug and 13 the placebo. Baseline characteristics for the
two groups are reported in Table 1. One patient in the active drug
group did not show up at week 4; thus, 12 patients in this group
and 13 patients in the placebo group were available for the per-
protocol analysis. There was no significant difference between the
groups in fatigue score at week 4 when adjusting for baseline
values, p=0.19 (ANCOVA). There was a highly significant
improvement in fatigue at week 4, compared to baseline, in the
group on the active drug (p=0.005), and an almost significant
improvement in the placebo treated group, p=0.053 (Friedman
Test), Figure 2. The mean improvement in fatigue VAS at week 4
was 37% (SE 10.2%) in the active drug group and 13.5% (SE
8.0%) in the placebo group. Six out of 12 patients (50%) on the
active drug and one out of 13 patients on placebo reported .50%
reduction in fatigue VAS score from baseline to week 4, p=0.03
(Fisher’s exact test). The relative risk of experiencing a 50%
Figure 1. Flowchart of inclusion in the study. The pilot-study was conducted in 2008 and the main study in 2010. All patients underwent the
same procedures. PSS, primary Sjo ¨gren’s syndrome; FSS, Fatigue Severity Scale.
doi:10.1371/journal.pone.0030123.g001
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the active drug group compared to the placebo group.
The intention to treat-principle specifies that all randomized
patients must be included in the analysis, and according to this the
fatigue VAS score at week 4 was carried forwards from the score
obtained at week 2 for the patient missing at week 4. The results
remained unchanged by this approach, with no difference between
groups in the primary endpoint (ANCOVA, p=0.163). The patient
had a .50% reduction in fatigue VAS score and the difference in
numbers of patients in each group who achieved .50% reduction
in fatigue remained significant (Fisher’s excact test, p=0.03).
There were no significant changes in FSS scores in either
treatment group during the study, Table 2. Fatigue levels returned
to baseline one week after the last injection in both groups (week 5).
The mean change in the neutrophil cell count from week 0 to
week 4 was 219.6% (SE 9.7%) in the active drug group and
212.8% (SE 5.2%) in the placebo group. However, the mean
neutrophil count was still within the normal range in both groups
at week 4. Complement C3 and C4 levels had a mean change of
25.4% (SE 3.0%) and 216.3% (SE 5.3%) in the active drug
group, and a mean change of 22.1% (SE 1.1%) and 25.2% (SE
2.2%) in the placebo group from week 0 to week 4. Other
laboratory measures, including autoantibodies, remained un-
changed in both groups.
Safety
Two serious adverse events (SAE) were observed in each group.
One patient on anakinra developed a severe injection site reaction
and stopped medication on day 8. She was hospitalised on day 11
due to fever, malaise, and persistent skin changes. The condition
improved after treatment with antihistamines, and she could
restart the medication on day 15. She was not treated with
corticosteroids. Another patient in the active drug group did not
attend the week 4 visit due to gastroenteritis. She improved
spontaneously and no further action was taken. In the placebo
group, one patient developed chest pain and was hospitalized on
day 18. No cause was found and she was able to restart the
medication on day 22. Another patient in the placebo group got
diarrhoea on day 34 and was hospitalized. He was diagnosed with
diverticulitis and treated with antibiotics.
Three patients, two on the active drug and one on placebo, had
a transient episode of neutropenia. White blood cell count
normalised spontaneously during continued treatment according
to the protocol. Injection site reactions were common and
occurred in seven of the 13 patients on the active drug (54%),
and in two on placebo (15%). Apart from the one reported as a
SAE, injection site reactions were transient and mild, with a
burning sensation as the main symptom in the placebo group.
Discussion
This randomised, double-blind, placebo-controlled trial of IL-1
blockade did not show a significant reduction in fatigue after
treatment with IL-1 inhibition based on the primary endpoint
analysis, while the post-hoc analysis indicate a possible positive
effect. There are several possible explanations for this finding: One
explanation is that IL-1 does not substantially influence fatigue in
pSS, and that other factors leading to fatigue are more important
in this setting such as depression, sleep-disorders and autonomic
dysfunction [9]. As our intention was to investigate somatic factors
associated with fatigue, patients with moderate to serious
depression were excluded, and only one of the patients used
prescription drugs against insomnia. Autonomic dysfunction was
not evaluated systematically, but none of the patients spontane-
ously reported these types of symptoms. Therefore, we believe
these factors are less important in this study.
Another explanation is that the small number of subjects led to
low statistical power and therefore we could not confirm an actual
effect of IL-1 inhibition on fatigue. In the post-hoc analysis, half of
the patients in the active drug group did report a 50% reduction in
fatigue VAS score, compared to one patient in the placebo group.
Although not supported by the primary outcome measure, this
may indicate that IL-1 inhibition influences fatigue in patients with
pSS. This observation is in line with our primary hypothesis that a
blockade of the IL-1 receptor should lead to reduction of fatigue
due to reduced IL-1b signalling in the brain. This is analogous to
the concept of sickness behaviour in animals, which is predom-
inantly incited by IL-1b. The intratechal production of IL-1b is
thought to reflect the peripheral production but at a significantly
lower concentration [27]. IL-1b induces inflammation in the
periphery, while IL-1b inside the BBB acts as a transmitter
substance which causes behavioural effects without major brain
inflammation [28].
We previously documented an increased concentration of the
naturally occurring IL-1Ra in the cerebrospinal fluid (CSF) of
patients with pSS and fatigue [7]. In cases of chronic inflammation
this increased level is thought to counterbalance increased IL-1b;
thus, it acts as a surrogate marker of IL-1b, which is extremely
difficult to measure in CSF. Peripherally produced IL-1b can cross
the BBB in selected areas by active transport and can activate the
vagus and other afferent nerves with consequent signalling to the
brain [27]. Further, peripherally produced cytokines activate the
Table 1. Selected demographic and laboratory variables at
inclusion for 26 patients with primary Sjo ¨gren’s syndrome (pSS).
Active drug Placebo
No. of subjects 13 13
Gender (Male/Female) 4/9 3/10
Age at baseline, years* 55 [36–80] 54 [32–75]
Disease duration, years* 5 [1–17] 8 [0–16]
BMI, kg/m
2**
{ 23.263.4 22.562.4
Haemoglobin, g/L** 139614 137612
Leukocytes 10
9/L** 5.561.5 6.261.3
CRP mg/L** 2.162.3 3.163.4
ESR mm/h** 10661 1 67
TSH mIU/L** 2.160.8 1.860.9
Anti-SSA/Ro antibody (%) 13 (100) 10 (77)
Anti-SSB/La antibody (%) 7 (54) 6 (46)
Disease modifying treatment 8 (62) 9 (69)
Antimalarial drugs (%) 4 (31) 7 (54)
Prednisolone (%) 5 (38) 2 (15)
Azathioprine (%) 4 (31) 1 (8)
Leflunomid (%) 0 (0) 1 (8)
Thyroxin (%) 1 (8) 4 (31)
Betablockers (%) 1 (8) 2 (15)
*Represents median and range.
**Represents mean 6 standard deviation (SD).
{BMI, body mass index. Available for the 18 patients in 2010 study only.
Numbers in parentheses represent percentages.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TSH, thyroid-
stimulating hormone.
doi:10.1371/journal.pone.0030123.t001
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may also be a major pathway for brain signaling [29]. A recent
study reports how infusion of a monoclonal antibody to TNF-a
inhibits pain responses in the CNS within 24 hours [30]. This
monoclonal antibody does not cross the BBB, and the observed
CNS effect is probably due to reduced activation of the
endothelium in the BBB [30]. This indicates that a reduction in
circulating levels of IL-1 in the periphery may influence fatigue
signalling in the brain. In the current study, IL-1Ra was
administered subcutaneously, but it also has the potential to cross
the BBB by a saturable transport system [16,31,32].
The pSS patients included in this study showed large variations
in fatigue scores at inclusion and during the study, and we believe
this is the main reason we were not able to show a significant
reduction in fatigue in the primary outcome measure. Also,
according to the sample size calculation, 30 patients were needed
to show a 25 point improvement on fatigue VAS, but for practical
reasons this many patients could not be included.
FSS scores were constant in both treatment groups during the
study, a phenomenon possibly explained by descriptive scales
being less sensitive to change than visual analogue scales [33].
Another explanation for the lack of change in FSS is that it
measures a dimension of fatigue not influenced by IL-1
modulation.
There is no established treatment regimen for fatigue in
autoimmune diseases. Dass and colleagues recently investigated
the effect of the B-cell depleting agent, rituximab, on fatigue in 17
pSS patients. This study found that seven out of eight patients
treated with rituximab and five out of nine patients treated with
placebo reported a .20% reduction in fatigue VAS at six months
[25]. Another study of rituximab in pSS also reported an
improvement in fatigue as measured by the Multidimensional
Fatigue Inventory (MFI) [34]. Similar findings are reported in
other autoimmune diseases, and the TNF-a inhibitor etanercept
was shown to relieve fatigue in a cohort of psoriasis patients [35].
These findings, together with the current results, indicate that one
mechanism for fatigue in pSS is immune activation. The use of
biological drugs is therefore an exciting new approach to fatigue
treatment in chronic inflammatory diseases. This class of drugs
may influence fatigue generating pathways.
Several studies point to an influence of IL-1 on mood and
depression [36]. Depressed patients were excluded from the
current study because we wanted to explore the influence of IL-1
on fatigue in non-depressed patients. However, we believe it would
be of great interest to map the effects of newer biological drugs on
Figure 2. Median fatigue at baseline and during the study. Brackets represent inter-quartile range. VAS, visual analogue scale.
doi:10.1371/journal.pone.0030123.g002
Table 2. Fatigue and depression scores at inclusion and
during the study.
Baseline Week 0 Week 2 Week 4 Week 5
Fatigue VAS* A: 65 [45–78] 66 [42–76] 60 [29–71] 34 [17–71] 74 [46–82]
P: 72 [55–80] 69 [52–86] 51 [44–70] 60 [50–63] 72 [47–80]
FSS** A: 5.661.0 5.661.2 5.361.1 5.161.1 5.660.9
P: 5.760.8 5.661.1 4.961.2 4.761.3 5.261.0
BDI* A: 5 [3–11] 4 [0–10]
P: 8 [6–12] 7 [2–14]
*Represents median and interquartile range.
**Represents mean 6 SD.
A, active drug; BDI, Beck Depression Inventory; FSS, Fatigue Severity Scale; P,
placebo; VAS, visual analogue scale.
doi:10.1371/journal.pone.0030123.t002
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include measures of both fatigue and depression.
Safety
Based on our limited study results, anakinra appears to be safe
in pSS patients. Side effects or SAEs in the active drug group were
not more prevalent than in the placebo group. However, as the
study included only 13 patients in the active drug group, and
treatment was given for four weeks only, it is not possible to
estimate the long-term safety of anakinra in pSS.
Strengths and limitations
There are several limitations to this study. The number of
subjects is small; reflecting the difficulty in selecting patients not
biased by depression, drugs, or other factors that could influence
fatigue [24]. The patients included may not represent the whole
pSS cohort, as the percentage of male patients (27%) was higher
than expected, and most patients were using at least one disease
modifying drug. Also, we used a simple randomisation, which may
have lead to unbalanced arms. In a small study like this it would at
best be possible to stratify the subjects on one, possibly two
variables [37]. However, it is not clear which variables are the
optimal ones to employ. There is no known association in pSS
between fatigue and age, disease duration, laboratory values or
other clinical parameters that could be used for stratification at
inclusion. Neither did we stratify according to fatigue score, as
FSS.3 was a criteria for inclusion. For this reason, we decided a
1:1 allocation was the best approach.
We did not investigate the relationship between social factors
and fatigue, as the small patient number did not allow subgroup
analysis. We used two instruments to measure fatigue; the fatigue
VAS and the FSS. Both of these scales are unidimensional, and the
use of a multidimensional scale might have provided extra
information on the origin of fatigue.
The placebo effect was quite strong in this study, as both groups
had a reduction in fatigue at week 2 close to significance. This is
not unexpected. Figure 2 illustrates how the placebo group
reported more fatigue at week 4, while the treatment group had a
further decline in fatigue. We interpret this as a reduction in the
placebo-effect at week 4.
We did not measure pSS disease activity during the study. The
lack of a disease activity instrument that is sensitive to change has
been a limitation in intervention studies of pSS patients. Recently
an instrument for this purpose was developed and it is reportedly
accurate in detecting changes in disease activity [38].
Local skin reactions are common following anakinra injections
and are well known to patients. Thus, some patients may have
guessed their allocated treatment; we can not exclude the
possibility that this may have affected the final results. However,
two of the patients in the placebo group also reported skin
reactions.
This study was conducted in two phases. Theoretically, there
may have been different patient handling and different results in
the two phases. Four patients were randomised to active drug and
four to placebo in 2008; in 2010, there were nine patients in each
group. If only the results from the 2010 study are analysed, four
out of eight patients receiving anakinra versus one out of nine
patients receiving the placebo demonstrated a $50% reduction in
fatigue from baseline, with a trend towards statistical significance
when comparing the groups (p=0.09).
Strengths of the study are the study design, the inclusion of only
well characterised patients according to the 2002 American-
European Consensus Group criteria and that all patients
completed the assigned treatments with none lost to follow-up.
There is a general lack of treatment-studies in pSS, and a lack of
studies of fatigue-specific treatment in particular. This study brings
new knowledge to the field. The study is fully investigator initiated
and represents a novel approach to fatigue research.
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